The PLSG's $200,000 investment in ThermalTherapeutics Systems, Inc. will help with the development of a prototype pump for delivering chemotherapy more effectively. The TTS device will deliver both intraperitoneal chemotherapy (IPC) and intraperitoneal hyperthermic chemotherapy (IPHC) to treat metastastic abdominal cancers regardless of primary site, especially ovarian and colon cancer. No device currently exists which has been specifically designed to treat advanced abdominal cancers. The ability to deliver intraperitoneal hyperthermic treatment for disseminated abdominal cancer, therefore, represents a significant advancement in the treatment for a sizable population of cancer patients; substantially improving the quality of life for those undergoing treatment.
The attention that both IPC and IPHC are receiving for the treatment of ovarian, colon, rectal and additional abdominal cancers creates potential for the TTS product to make an important impact on cancer treatment.
About the Pittsburgh Life Sciences Greenhouse (PLSG)
The PLSG invests in and supports the growth of biosciences companies in
southwestern Pennsylvania. The PLSG has investment and business growth
programs to increase the linkage between research, technology and
commercialization; nurture and develop entrepreneurial bioscience
|SOURCE Pittsburgh Life Sciences Greenhouse|
Copyright©2007 PR Newswire.
All rights reserved